Table 5.

Multivariable multinomial logistic regression analysis of distribution of answers to the structured interview.

Question		Answers compared to the reference levela	Odds Ratio (95% CI)	p-value
Q1	Female vs. Male	Moderately	1.73 (0.75–4.00)	0.20
		Quite a bit/Extremely	3.08 (1.26–7.52)	0.01
	Comorbidity vs. No comorbidity	Moderately	0.46 (0.19–1.10)	0.08
		Quite a bit/Extremely	2.85 (0.83–9.76)	0.10
	Previous surgery/pulmonary RT	Moderately	1.29 (0.56–2.96)	0.55
		Quite a bit/Extremely	3.75 (1.50–9.37)	<0.001
Q2	Female vs. Male	Moderately	3.43 (1.51–7.79)	0.003
		Quite a bit/Extremely	3.42 (1.29–9.07)	0.01
	Comorbidity vs. No comorbidity	Moderately	0.98 (0.40–2.39)	0.97
		Quite a bit/Extremely	4.51 (0.95–21.0)	0.06
Q3	Comorbidity vs. No comorbidity	Moderately	1.04 (0.40–2.79)	0.94
		Quite a bit/Extremely	1.52 (0.49–4.67)	0.47
	Intravenousb vs. TKI	Moderately	0.51 (0.19–1.38)	0.18
		Quite a bit/Extremely	0.23 (0.08–0.68)	0.008
	Months from cancer diagnosis: (3,12] vs. ≤ 3	Moderately	0.72 (0.18–2.91)	0.64
		Quite a bit/Extremely	1.20 (0.11–13.7)	0.88
	>12 vs. ≤3	Moderately	0.83 (0.23–3.03)	0.78
		Quite a bit/Extremely	2.70 (0.29–24.8)	0.38
Q9	Previous surgery/pulmonary RT	COVID-19	1.52 (0.61–3.81)	0.37
		Both equally	0.79 (0.29–2.17)	0.64
	Intravenousb vs TKI	COVID-19	0.91 (0.36–2.30)	0.84
		Both equally	2.93 (0.85–10.1)	0.09
	Months from cancer diagnosis: (3,12] vs. ≤ 3	COVID-19	4.43 (0.61–32.7)	0.14
		Both equally	3.75 (0.92–15.2)	0.06
	12 vs. ≤3	COVID-19	6.58 (1.08–40.1)	0.04
		Both equally	1.53 (0.37–6.34)	0.56

^aReference levels are: not at all/a little for Q1, Q2, and Q3, Oncological disease for Q9; ^bIntravenous: CT,CT+IO, CT+RT, IO.

TKI, tyrosine kinase inhibitors; CT, chemotherapy; IO, immunotherapy; RT, radiotherapy.